Tuning tumor-specific T-cell activation: A matter of costimulation?

Trends in Immunology

Volumn 23, Issue 5, 2002, Pages 240-245

  Abken, Hinrich ^a   Hombach, Andreas ^a   Heuser, Claudia ^c   Kronfeld, Kai ^b   Seliger, Barbara ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; BISPECIFIC ANTIBODY; CANCER ANTIBODY; CANCER VACCINE; CD134 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 2; MONOCLONAL ANTIBODY; OX40 ANTIBODY; RECOMBINANT RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN BINDING; ANTIGEN RECOGNITION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY;

ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES;

EID: 0036570957     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(02)02180-4     Document Type: Review

References (54)

1. Signaling through CD28 and CTLA-4 controls two distinct forms of T-cell anergy
2. CD4-help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation
3. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
4. Manipulation of costimulatory signals to enhance antitumor T-cell responses
5. Vascular attack by 5,6-dimethylanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci
6. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors
7. Enhancement of the anti-tumor immune response using a combination of interferon-γ and B7 expression in an experimental mammary carcinoma
8. GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice
9. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells
10. Engineering and characterization of a novel fusion protein incorporating B7.2 and an anti-ErbB-2 single-chain antibody fragment for the activation of Jurkat T cells
11. Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant
12. Targeting of a B7-1 (CD80) immunoglobulin-G fusion protein to acute myeloid leukemia blasts increases their costimulatory activity for autologous remission T cells
13. + T-helper and a T-killer cell
14. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
15. Help for cytotoxic T-cell responses is mediated by CD40 signalling
16. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
17. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
18. Engagement of the OX40 receptor in vivo enhances antitumor immunity
19. Enhancement of tumor immunity by CTLA-4 blockade
20. Manipulation of T-cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
21. Enhanced induction of antitumor T-cell responses by cytotoxic T-lymphocyte-associated-molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages
22. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T-lymphocyte-associated-antigen-4 (CTLA-4) blockade immunotherapy
23. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T-lymphocyte responses
24. In vivo blockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor-antigen-specific tolerance
25. + T-cell- and IL-2-dependent mechanism
26. Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells?
27. +T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC-antigen- and fas-independent fashion
28. + cutaneous lymphoma cells
29. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin-2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target-cell lysis
30. Distinct motifs within CD28 regulate T-cell proliferation and induction of Bcl-xL
31. OX40: Targeted immunotherapy - Implications for tempering autoimmunity and enhancing vaccines
32. ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement
33. The LFA-1/ICAM-1 cell-adhesion pathway is involved in tumor-cell lysis mediated by bispecific monoclonal-antibody-targeted T lymphocytes
34. T-cell costimulation by the TNF ligand BAFF
35. Endothelial-cell costimulation of T-cell activation through CD58-CD2 interactions involves lipid-raft aggregation
36. The T-cell receptor as a multicomponent signalling machine
37. Involvement of the protein tyrosine kinase p56lck in T-cell signalling and thymocyte development
38. + T cells in vitro
39. CD4 help-independent induction of cytotoxic CD8 cells to allogeneic P815 tumor cells is absolutely dependent on costimulation
40. CD28/B7 costimulation: A review
41. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation
42. CD28 and apoptosis
43. Signaling through OX40 (CD134) breaks peripheral T-cell tolerance
44. Combination immunotherapy of B16 melanoma using anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)- and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
45. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade
46. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb
47. Melphalan and other anticancer modalities up-regulate B7-1 gene expression in tumor cells
48. Antigen-specific targeting of CD28-mediated T-cell co-stimulation using chimeric single-chain antibody variable fragment CD28 receptors
49. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes
50. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product
51. Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes
52. Tumor-specific T-cell activation by recombinant immunoreceptors: CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule
53. Functional expression of chimeric receptor genes in human T cells
54. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor